Dex as Analgesic Adjuvant in OSA Patients

Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Obstructive Sleep Apnea

In brief

The purpose of this study is to assess whether intravenous peri-operative Dexmedetomidine reduces opioid requirements and or improves pain control after Uvulopalatopharyngoplasty (UPPP) in patients with obstructive sleep apnea (OSA).

Key facts

Study ID

NCT03613558

Run by

Montefiore Medical Center

People needed

0

Starts

2014-07-01

Expected to finish

2015-06-01

Last updated by the study team

2018-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Patients scheduled for UPPP
• Patients with diagnosis of OSA via polysomnography
• American Society of Anesthesiology (ASA) classification 3 or lower

You may not qualify if…

• Bradycardia as defined as resting heart rate <60 Beats per min (BPM) or symptomatic
• Any degree of heart block diagnosed by ECG
• Hypotension as defined as <20% from baseline or symptomatic
• Liver failure, (two fold rise in liver enzymes)
• Chronic Kidney Disease (CKD) III or greater
• History of allergy to opioids or dexmedetomidine
• ASA classification 4 or higher
• ICU or Step down admission
• Difficult airway as defined by previous history of difficult intubation or requiring a fiberoptic intubation.

Where it is running

• Montefiore Medical Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.